"I want to share my story and help others like myself living with MPN. MPN Research Foundation has been that source of community support for my family and I as we learn to deal with living with a disease on a daily basis."

Novartis enters into partnership with Incyte

Novartis will collaborate with Incyte on the further development of two of Incyte Corp.'s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process. If approved, this will be the first FDA approved treatment for myelfibrosis.

For more information:

Press release


BioWorld

 

Your donation goes a long way.

Learn more about how you can help support the MPN Research Foundation and the impact your contributions can make.

Donate Now
 
 
 

Subscribe

Want to learn more about the MPN Research Foundation? Sign up for our Newsletter and Research Alerts!

Newsletter Signup

 
 

Connect with Us

MPN Research Foundation wants to hear from you. Connect with us through our social networks or send us an email.

Email Facebook Twitter LinkedIn